Short Interest in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Declines By 30.8%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 28,700 shares, a drop of 30.8% from the March 15th total of 41,500 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average daily volume of 200,700 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new position in shares of Creative Medical Technology during the third quarter valued at about $113,000. Vanguard Group Inc. bought a new stake in Creative Medical Technology in the first quarter worth about $98,000. State Street Corp bought a new stake in Creative Medical Technology in the first quarter worth about $90,000. XTX Topco Ltd bought a new stake in Creative Medical Technology in the first quarter worth about $68,000. Finally, Geode Capital Management LLC raised its position in Creative Medical Technology by 261.8% in the first quarter. Geode Capital Management LLC now owns 124,224 shares of the company’s stock worth $62,000 after acquiring an additional 89,886 shares during the period. 1.42% of the stock is owned by institutional investors.

Creative Medical Technology Trading Down 4.7 %

Shares of CELZ traded down $0.25 during trading hours on Friday, reaching $5.21. 4,124 shares of the stock traded hands, compared to its average volume of 22,546. The stock has a fifty day simple moving average of $4.94 and a 200 day simple moving average of $4.69. Creative Medical Technology has a 52 week low of $3.93 and a 52 week high of $10.28. The company has a market cap of $7.09 million, a price-to-earnings ratio of -1.40 and a beta of 2.21.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings results on Friday, March 22nd. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.08). Analysts predict that Creative Medical Technology will post -4.68 earnings per share for the current fiscal year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility.